S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
Log in
OTCMKTS:CGNH

CardioGenics Stock Forecast, Price & News

$0.02
0.00 (0.00 %)
(As of 09/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.02
$0.13
Volume55,000 shs
Average Volume135,497 shs
Market Capitalization$1.78 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.31
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.80 out of 5 stars


Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CGNH
CUSIPN/A
Phone905-673-8501

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees4
Market Cap$1.78 million
Next Earnings DateN/A
OptionableNot Optionable
$0.02
0.00 (0.00 %)
(As of 09/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGNH News and Ratings via Email

Sign-up to receive the latest news and ratings for CGNH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CardioGenics (OTCMKTS:CGNH) Frequently Asked Questions

How has CardioGenics' stock been impacted by Coronavirus (COVID-19)?

CardioGenics' stock was trading at $0.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CGNH stock has increased by 50.0% and is now trading at $0.0150.
View which stocks have been most impacted by COVID-19
.

Who are some of CardioGenics' key competitors?

What other stocks do shareholders of CardioGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CardioGenics investors own include Trinity Biotech (TRIB), Rock Creek Pharmaceuticals (RCPIQ), CEL-SCI (CVM) and Canopy Growth (CGC).

Who are CardioGenics' key executives?

CardioGenics' management team includes the following people:
  • Dr. Yahya Abdul Gawad MB, Ch.B., M.D., MSc., Chief Exec. Officer and Director (Age 61)
  • Mr. James A. Essex CA, MBA, Chief Financial Officer (Age 70)
  • Ms. Linda J. Stering F.Inst.L.C.O., Sec. & Director (Age 58)

What is CardioGenics' stock symbol?

CardioGenics trades on the OTCMKTS under the ticker symbol "CGNH."

How do I buy shares of CardioGenics?

Shares of CGNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CardioGenics' stock price today?

One share of CGNH stock can currently be purchased for approximately $0.02.

How big of a company is CardioGenics?

CardioGenics has a market capitalization of $1.78 million. CardioGenics employs 4 workers across the globe.

What is CardioGenics' official website?

The official website for CardioGenics is www.cardiogenics.com.

How can I contact CardioGenics?

CardioGenics' mailing address is 6295 Northam Drive Unit 8, Mississauga A6, L4V 1W8. The company can be reached via phone at 905-673-8501 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.